Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Achilles Therapeutics PLC ADR (ACHL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/20/2025: ACHL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 2.62% | Avg. Invested days 49 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 63.22M USD | Price to earnings Ratio - | 1Y Target Price 0.5 |
Price to earnings Ratio - | 1Y Target Price 0.5 | ||
Volume (30-day avg) 1836733 | Beta 1.25 | 52 Weeks Range 0.63 - 1.51 | Updated Date 04/6/2025 |
52 Weeks Range 0.63 - 1.51 | Updated Date 04/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.66 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.17% | Return on Equity (TTM) -52.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -17013838 | Price to Sales(TTM) - |
Enterprise Value -17013838 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.66 | Shares Outstanding 41100000 | Shares Floating 20847584 |
Shares Outstanding 41100000 | Shares Floating 20847584 | ||
Percent Insiders 6.29 | Percent Institutions 83.1 |
Analyst Ratings
Rating 2 | Target Price 0.5 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Achilles Therapeutics PLC ADR
Company Overview
History and Background
Achilles Therapeutics PLC ADR is a biopharmaceutical company focused on developing precision T cell therapies targeting clonal neoantigens expressed on cancer cells. Founded in 2016, it leverages its PELEUS platform to identify and target these neoantigens.
Core Business Areas
- T Cell Therapy Development: Developing personalized T cell therapies targeting clonal neoantigens for solid tumors.
- PELEUS Platform: Utilizing its proprietary PELEUS platform to identify and validate clonal neoantigens.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its T cell therapy candidates.
Leadership and Structure
The company is led by Iraj Ali as CEO. The organizational structure includes departments focused on research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- ATL001: A personalized T cell therapy targeting clonal neoantigens in NSCLC. Currently in Phase 1/2a clinical trials. Competitors: Several companies are developing T-cell therapies, including Adaptimmune Therapeutics and Iovance Biotherapeutics. Market share information not publicly available.
- ATL002: A personalized T cell therapy targeting clonal neoantigens in melanoma. Currently in Phase 1/2a clinical trials. Competitors: Similar to ATL001, competes with companies developing T-cell therapies like Adaptimmune Therapeutics and Iovance Biotherapeutics. Market share information not publicly available.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by increasing demand for personalized cancer treatments. It is competitive and highly regulated.
Positioning
Achilles Therapeutics is positioned as a leader in clonal neoantigen T cell therapy, leveraging its PELEUS platform. Its competitive advantage lies in its ability to specifically target clonal neoantigens, potentially leading to more effective and durable responses.
Total Addressable Market (TAM)
The total addressable market for cell therapies is projected to reach billions of dollars. Achilles Therapeutics is positioned to capture a portion of this market by addressing unmet needs in solid tumors.
Upturn SWOT Analysis
Strengths
- Proprietary PELEUS platform for neoantigen identification
- Personalized T cell therapy approach
- Focus on solid tumors
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Early stage clinical development
- High development costs
- Regulatory hurdles
- Competition in the cell therapy space
- Reliance on successful clinical trial outcomes
Opportunities
- Expansion into new cancer indications
- Partnerships with pharmaceutical companies
- Advancements in cell therapy technologies
- Positive clinical trial results
- Regulatory approvals
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory changes
- Economic downturn
- Patent challenges
Competitors and Market Share
Key Competitors
- ADAP
- IOVA
Competitive Landscape
Achilles Therapeutics competes in the cell therapy space, which is crowded and competitive. It's differentiation lies in its PELEUS platform and clonal neoantigen targeting approach. They are small compared to ADAP and IOVA.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth unavailable due to lack of detailed financial data
Future Projections: Future projections depend on successful clinical trial outcomes and regulatory approvals. Analyst estimates are unavailable.
Recent Initiatives: Focus on advancing ATL001 and ATL002 through clinical trials, expanding PELEUS platform capabilities, and exploring new partnerships.
Summary
Achilles Therapeutics is a biopharmaceutical company focused on developing precision T cell therapies targeting clonal neoantigens. It's PELEUS platform is unique, but it is early stage and carries the risk of clinical development. Financial information is scarce, limiting deep analysis and evaluation. They must obtain clinical approval to make it into a profitable endeavor. The company's fate relies heavily on successful clinical trial outcomes.
Similar Companies
ADAP
Adaptimmune Therapeutics Plc
ADAP
Adaptimmune Therapeutics Plc
IOVA
Iovance Biotherapeutics Inc
IOVA
Iovance Biotherapeutics Inc
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Achilles Therapeutics PLC ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-03-31 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 204 | Website https://www.achillestx.com |
Full time employees 204 | Website https://www.achillestx.com | ||
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.